iifl-logo

Pfizer Ltd Board Meeting

4,017.65
(-0.46%)
Apr 2, 2025|11:59:57 AM

Pfizer CORPORATE ACTIONS

02/04/2024calendar-icon
02/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting21 Feb 202521 Feb 2025
Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane
Board Meeting31 Jan 202524 Jan 2025
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Board Meeting to consider and take on record the Unaudited Financial Results for the quarter and nine months ended December 31 2024 Outcome of the Board Meeting- Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 31/01/2025)
Board Meeting28 Oct 202421 Oct 2024
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended September 30 2024. Outcome of the Board Meeting-Unaudited Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement dated on: 28/10/2024)
Board Meeting29 Jul 202422 Jul 2024
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results for the quarter ended June 30, 2024, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 4.00 p.m. and concluded at 7.25 p.m. Also please find enclosed the Limited Review Report by our Statutory Auditors, M/s. B. S. R. & Co., LLP, in respect of the said results Intimation pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure) Regulations, 2015. (As per BSE Announcement Dated on 29/07/2024)
Board Meeting17 May 20246 May 2024
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31 2024 and to consider recommendation of dividend if any for the Financial Year ended March 31 2024. The Board of Directors has at its Meeting held today, i.e., May 17, 2024, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the financial year ended March 31, 2024. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 6, 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Audited financial results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024, Declaration with respect to Audit Report with unmodified opinion and the Auditors Report by our Statutory Auditors, M/s. B S R & Co., LLP. The Audited financial results for the year ended March 31, 2024 were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 3:00 p.m. and concluded at 7:15 p.m (As Per NSE Announcement Dated on 17.05.2024) We refer to our letter dated May 17, 2024, informing you about the Audited Financial Results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024 and Declaration with respect to unmodified opinion. We wish to bring to your notice that by oversight the Auditors Report was not attached with the said filing. Please find attached Auditors Report dated May 17, 2024, by our Statutory Auditors, M/s. B.S.R. & Co. LLP. Please note that there are no changes in the Audited Financial Results for the year ended March 31, 2024, published on May 17, 2024. Request you to please take the above on record. Read less.. (As Per BSE Announcement Dated on 27.05.2024)

Pfizer: Related News

Pfizer Partners with Mylan to Boost Ativan and Pacitane Sales in India
23 Feb 2025|11:51 PM

Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.

Read More
Pfizer Ties Up with Mylan to Boost Ativan and Pacitane Sales in India
21 Feb 2025|05:31 PM

The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.

Read More
Pfizer India Q3 Profit Slips 2% YoY
31 Jan 2025|11:34 PM

Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24

Read More
Pfizer reports 61% YoY profit surge in Q1 2024
30 Jul 2024|09:44 AM

At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.